GET DAILY SIGNALSTrulieve (TRLV) Delivers Margin Expansion and Positive Earnings in Q3 2026
Key Takeaways
- Trulieve Cannabis Corp. (TRLV) reported third-quarter 2026 revenue of $230.2 million, up 4% versus its medical-only comparable from a year ago and beating the consensus estimate of roughly $226 million.
- Gross margin expanded to 64%, with gross profit of $148 million, reflecting operational efficiencies and disciplined promotional activity.
- Net income attributable to common shareholders was about $1 million, a swing from a $27 million loss a year earlier; adjusted net income was $18 million, or $0.09 per diluted share.
- Adjusted EBITDA reached $89 million, a 39% margin, up from a 36% margin a year ago.
- The company generated $74 million in operating cash flow and $45 million in free cash flow, ending the quarter with $327 million in cash and repaying a $65 million mortgage.
Earnings Context and Why It Matters
Trulieve’s third-quarter 2026 results represent its first full quarter as an NYSE-listed company and its first reporting period under a medical-only structure after the June 2026 deconsolidation of Harvest’s mixed operations. These changes complicate direct year-over-year comparisons, yet they provide a clearer view of the core U.S. medical cannabis business. With federal rescheduling of state-licensed medical marijuana to Schedule III and final DEA registrations in place, the quarter highlights how Trulieve’s margins and cash generation are progressing amid supportive regulatory developments.
Reported Results
For the quarter ended September 30, 2026, Trulieve posted revenue of $230.2 million. The headline number declined from $288.2 million a year earlier, but that comparison is skewed by the Harvest deconsolidation. On a like-for-like medical-only basis, revenue rose 4% and topped management’s guidance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Gross profit reached $148 million, for a 64% gross margin, up from 59% in the prior-year period. Net income attributable to common shareholders came in at approximately $1 million, versus a $27 million loss a year earlier. Adjusted net income was $18 million, or $0.09 per diluted share, broadly in line with expectations.
Adjusted EBITDA totaled $89 million, a 39% margin compared with 36% a year ago. Operating cash flow was $74 million, free cash flow was $45 million, and cash on the balance sheet stood at $327 million at quarter-end.
Market Reaction and Investor Sentiment
Investor focus has centered more on earnings quality than the top-line figure. Gross-margin expansion, the shift to positive net income, and strong free cash flow point to greater efficiency in the medical-only business post-restructuring. The results cleared a modest analyst bar, especially on margins and cash generation, underscoring the advantages of Trulieve’s scale in Florida and early traction in Georgia and Pennsylvania. The early repayment of a $65 million mortgage also signaled balance-sheet discipline. Still, the smaller consolidated revenue base and dependence on state-level regulatory moves leave some investors cautious on the pace of future growth.
Forward Outlook and Key Factors to Monitor
Looking ahead, the key question is whether Trulieve can maintain its margin improvements while funding growth initiatives. Georgia remains a focal point, with patient counts now above 60,000 and plans underway for a tenth dispensary license plus wholesale distribution to independent pharmacies.
Texas offers longer-term potential, where the company has started building vertical operations and holds royalty-free licenses for Alien Labs and Connected products. Capital spending for these expansions may modestly affect near-term free cash flow, though the solid cash position provides room to maneuver.
On the regulatory side, relief from the 280E tax burden and completed DEA registrations should continue to support profitability. Investors will want to track gross-margin sustainability, promotional spending in Florida, and whether adjusted EBITDA margins remain in the high-30% range as new markets scale.
Exploring AI Tools for Stock Analysis
In my own research process, I frequently use Tickeron’s AI Screener to quickly filter stocks by technical patterns, fundamentals, and performance metrics. It helps surface relevant ideas and compare names like Trulieve against peers without manual effort, which has become a regular part of how I prepare for earnings reviews.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TRLV in upward trend: price rose above 50-day moving average on November 03, 2026
TRLV moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend. In 36 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on TRLV as a result. In 63 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for TRLV just turned positive on October 22, 2026. Looking at past instances where TRLV's MACD turned positive, the stock continued to rise in 26 of 33 cases over the following month. The odds of a continued upward trend are 79%.
Following a +4.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRLV advanced for three days, in 188 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for TRLV crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
TRLV broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TRLV entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TRLV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.911) is normal, around the industry mean (7.659). P/E Ratio (-4.696) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.470) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.947) is also within normal values, averaging (181.047).
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement